BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37544501)

  • 41. FERMT1 knockdown inhibits oral squamous cell carcinoma cell epithelial-mesenchymal transition by inactivating the PI3K/AKT signaling pathway.
    Wang X; Chen Q
    BMC Oral Health; 2021 Nov; 21(1):598. PubMed ID: 34814915
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Crosstalk between STAT5 activation and PI3K/AKT functions in normal and transformed mammary epithelial cells.
    Rädler PD; Wehde BL; Wagner KU
    Mol Cell Endocrinol; 2017 Aug; 451():31-39. PubMed ID: 28495456
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TNFAIP3 is required for FGFR1 activation-promoted proliferation and tumorigenesis of premalignant DCIS.COM human mammary epithelial cells.
    Yang M; Yu X; Li X; Luo B; Yang W; Lin Y; Li D; Gan Z; Xu J; He T
    Breast Cancer Res; 2018 Aug; 20(1):97. PubMed ID: 30111373
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies.
    Cipriano R; Miskimen KL; Bryson BL; Foy CR; Bartel CA; Jackson MW
    Oncotarget; 2013 May; 4(5):729-38. PubMed ID: 23676467
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting GOLM1 by microRNA-200a in melanoma suppresses cell proliferation, invasion and migration via regulating PI3K/Akt signaling pathway and epithelial-mesenchymal transition.
    Chen WY; Xu YY; Zhang XY
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6997-7007. PubMed ID: 31486500
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumor suppressor role of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in human mammary epithelial cells.
    Tordjman J; Majumder M; Amiri M; Hasan A; Hess D; Lala PK
    BMC Cancer; 2019 Jun; 19(1):561. PubMed ID: 31185986
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway.
    Zheng J; Liu C; Shi J; Wen K; Wang X
    Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34913077
    [TBL] [Abstract][Full Text] [Related]  

  • 48. G protein-coupled receptor 30 mediates cell proliferation of goat mammary epithelial cells via MEK/ERK&PI3K/AKT signaling pathway.
    Zhao Y; Liu H; Fan M; Miao Y; Zhao X; Wei Q; Ma B
    Cell Cycle; 2022 Oct; 21(19):2027-2037. PubMed ID: 35659445
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.
    Ramírez-Moya J; Wert-Lamas L; Santisteban P
    Oncogene; 2018 Jun; 37(25):3369-3383. PubMed ID: 29353884
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Elevated Expression of Zinc Finger Protein 703 Promotes Cell Proliferation and Metastasis through PI3K/AKT/GSK-3β Signalling in Oral Squamous Cell Carcinoma.
    Wang H; Deng X; Zhang J; Ou Z; Mai J; Ding S; Huo S
    Cell Physiol Biochem; 2017; 44(3):920-934. PubMed ID: 29176314
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tuftelin 1 (TUFT1) Promotes the Proliferation and Migration of Renal Cell Carcinoma
    Lin H; Zeng W; Lei Y; Chen D; Nie Z
    Pathol Oncol Res; 2021; 27():640936. PubMed ID: 34257606
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combretastatin A4 Regulates Proliferation, Migration, Invasion, and Apoptosis of Thyroid Cancer Cells via PI3K/Akt Signaling Pathway.
    Liang W; Lai Y; Zhu M; Huang S; Feng W; Gu X
    Med Sci Monit; 2016 Dec; 22():4911-4917. PubMed ID: 27966519
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DHEA inhibits proliferation, migration and alters mesenchymal-epithelial transition proteins through the PI3K/Akt pathway in MDA-MB-231 cells.
    Colín-Val Z; López-Díazguerrero NE; López-Marure R
    J Steroid Biochem Mol Biol; 2021 Apr; 208():105818. PubMed ID: 33508440
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of MicroRNA-19b on the Proliferation, Apoptosis, and Migration of Wilms' Tumor Cells Via the PTEN/PI3K/AKT Signaling Pathway.
    Liu GL; Yang HJ; Liu B; Liu T
    J Cell Biochem; 2017 Oct; 118(10):3424-3434. PubMed ID: 28322459
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation.
    Zheng Y; Xie L; Xu S; Yan W; Zhang H; Meng Y; Liu J; Wei X
    Mol Cell Biochem; 2021 Nov; 476(11):4031-4044. PubMed ID: 34244973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation.
    Williams MM; Vaught DB; Joly MM; Hicks DJ; Sanchez V; Owens P; Rahman B; Elion DL; Balko JM; Cook RS
    Breast Cancer Res; 2017 Sep; 19(1):105. PubMed ID: 28886748
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Irisin/FNDC5 inhibits the epithelial-mesenchymal transition of epithelial ovarian cancer cells via the PI3K/Akt pathway.
    Zhu T; Zhang W; Zhang Y; Lu E; Liu H; Liu X; Yin S; Zhang P
    Arch Gynecol Obstet; 2022 Sep; 306(3):841-850. PubMed ID: 35156135
    [TBL] [Abstract][Full Text] [Related]  

  • 58. GLI1 promotes cancer stemness through intracellular signaling pathway PI3K/Akt/NFκB in colorectal adenocarcinoma.
    Yang Z; Zhang C; Qi W; Cui Y; Xuan Y
    Exp Cell Res; 2018 Dec; 373(1-2):145-154. PubMed ID: 30321514
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rotenone restrains the proliferation, motility and epithelial-mesenchymal transition of colon cancer cells and the tumourigenesis in nude mice via PI3K/AKT pathway.
    Xue W; Men S; Liu R
    Clin Exp Pharmacol Physiol; 2020 Aug; 47(8):1484-1494. PubMed ID: 32282954
    [TBL] [Abstract][Full Text] [Related]  

  • 60. c-Src activation promotes nasopharyngeal carcinoma metastasis by inducing the epithelial-mesenchymal transition via PI3K/Akt signaling pathway: a new and promising target for NPC.
    Ke L; Xiang Y; Guo X; Lu J; Xia W; Yu Y; Peng Y; Wang L; Wang G; Ye Y; Yang J; Liang H; Kang T; Lv X
    Oncotarget; 2016 May; 7(19):28340-55. PubMed ID: 27078847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.